These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 18321157)

  • 21. The quality of economic evaluations of ultra-orphan drugs in Europe - a systematic review.
    Schuller Y; Hollak CE; Biegstraaten M
    Orphanet J Rare Dis; 2015 Jul; 10():92. PubMed ID: 26223689
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical studies in lysosomal storage diseases: past, present and future.
    Boudes PF
    Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():68-76. PubMed ID: 24380125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Lysosomal Storage Diseases: Challenges in Multiprofessional Patient Care with Enzyme Replacement Therapy].
    Das AM; Lagler F; Beck M; Scarpa M; Lampe C
    Klin Padiatr; 2017 May; 229(3):168-174. PubMed ID: 28464188
    [No Abstract]   [Full Text] [Related]  

  • 24. Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges.
    Desnick RJ; Schuchman EH
    Annu Rev Genomics Hum Genet; 2012; 13():307-35. PubMed ID: 22970722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emptying the stores: lysosomal diseases and therapeutic strategies.
    Platt FM
    Nat Rev Drug Discov; 2018 Feb; 17(2):133-150. PubMed ID: 29147032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. From Lysosomal Storage Diseases to NKT Cell Activation and Back.
    Pereira CS; Ribeiro H; Macedo MF
    Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28245613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A chaperone-mediated approach to enzyme enhancement as a therapeutic option for the lysosomal storage disorders.
    Pastores GM; Sathe S
    Drugs R D; 2006; 7(6):339-48. PubMed ID: 17073517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chaperone therapy for molecular pathology in lysosomal diseases.
    Suzuki Y
    Brain Dev; 2021 Jan; 43(1):45-54. PubMed ID: 32736903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic strategies to ameliorate lysosomal storage disorders--a focus on Gaucher disease.
    Sawkar AR; D'Haeze W; Kelly JW
    Cell Mol Life Sci; 2006 May; 63(10):1179-92. PubMed ID: 16568247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gene therapy for the lysosomal storage disorders.
    Cabrera-Salazar MA; Novelli E; Barranger JA
    Curr Opin Mol Ther; 2002 Aug; 4(4):349-58. PubMed ID: 12222873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene transfer approaches to the lysosomal storage disorders.
    Barranger JA; Rice EO; Swaney WP
    Neurochem Res; 1999 Apr; 24(4):601-15. PubMed ID: 10227692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ten plus one challenges in diseases of the lysosomal system.
    Grabowski GA; Whitley C
    Mol Genet Metab; 2017; 120(1-2):38-46. PubMed ID: 27923545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene therapy for lysosomal storage disorders.
    Ioannou YA; Enriquez A; Benjamin C
    Expert Opin Biol Ther; 2003 Aug; 3(5):789-801. PubMed ID: 12880379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disease models for the development of therapies for lysosomal storage diseases.
    Xu M; Motabar O; Ferrer M; Marugan JJ; Zheng W; Ottinger EA
    Ann N Y Acad Sci; 2016 May; 1371(1):15-29. PubMed ID: 27144735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene therapy progress and prospects: gene therapy of lysosomal storage disorders.
    Cheng SH; Smith AE
    Gene Ther; 2003 Aug; 10(16):1275-81. PubMed ID: 12883523
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene therapy for lysosomal storage diseases: the lessons and promise of animal models.
    Ellinwood NM; Vite CH; Haskins ME
    J Gene Med; 2004 May; 6(5):481-506. PubMed ID: 15133760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment prospects of lysosomal storage disorders].
    Reismann P; Tulassay Z
    Orv Hetil; 2008 Jun; 149(25):1171-9. PubMed ID: 18547894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification and use of biomarkers in Gaucher disease and other lysosomal storage diseases.
    Aerts JM; Hollak CE; van Breemen M; Maas M; Groener JE; Boot RG
    Acta Paediatr Suppl; 2005 Mar; 94(447):43-6; discussion 37-8. PubMed ID: 15895711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene therapy for lysosomal storage diseases: progress, challenges and future prospects.
    Seregin SS; Amalfitano A
    Curr Pharm Des; 2011; 17(24):2558-74. PubMed ID: 21774776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glycoprotein Non-Metastatic Protein B: An Emerging Biomarker for Lysosomal Dysfunction in Macrophages.
    van der Lienden MJC; Gaspar P; Boot R; Aerts JMFG; van Eijk M
    Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30586924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.